Latest Conference Articles

Genentech's Misfire on Kanjinti Creates Opening

Tony Hagen

April 28 2020

Taking an abundance of time to file a motion to block Kanjinti from coming to market, Genentech unwittingly may have tipped the scales in favor of biosimilar applicants.

WellDyne Executive Says Formulary Exclusions Are on the Rise

Tony Hagen

April 23 2020

Jeenal Patel, PharmD, BCGP, a formulary manager for WellDyne, said pharmacy benefit managers (PBMs) and employers are increasingly turning to formulary exclusions to control the rising cost of drugs.

AMCP Presenters Predict 4 More Biosimilar Launches in 2020

Tony Hagen

April 22 2020

Many additional biosimilars could be on the market by 2025, said presenters at the Academy of Managed Care Pharmacy eLearning Days virtual meeting.

Amid Good Signs on Biosimilars, COVID-19 Upends Drug Purchasing Patterns

Mary Caffrey

April 20 2020

Douglas M. Long, MBA, vice president of Industry Relations for IQVIA, surveyed COVID-19's effects on the pharmaceutical marketplace as he kicked off AMCP eLearning Days, a webinar series held in place of the annual meeting of the Academy of Managed Care Pharmacy (AMCP).

AMCP Posters Demonstrate Value of Biosimilars

Skylar Jeremias

April 20 2020

Posters presented at the Academy of Managed Care Pharmacy (AMCP) eLearning Days meeting this week from April 20 to 24 reveal important data on biosimilar utilization management, switching, and affordability.

Ruby Singh Previews the AMCP eLearning Days Virtual Meeting

April 17 2020

Ruby Singh, vice president for Education and Training, Academy of Managed Care Pharmacy (AMCP), speaks with Mary Caffrey about the upcoming AMCP eLearning Days, a virtual meeting that will take place April 20 to 24. AMCP's annual meeting was canceled due to coronavirus disease 2019 (COVID-19). This transcript is edited slightly for clarity.

Russia May Open the Spigot on Biosimilars

Skylar Jeremias

April 13 2020

Russia has rebuilt its pharmaceutical industry following the demise of the former Soviet-led government, and emerging companies such as Geropharm are looking for markets abroad.

Is Expanded Access a Route to Biosimilars Mired in Litigation?

Tony Hagen

March 23 2020

Legal and industry experts ponder whether expanded access to biosimilars is a way around patent thickets that slow the launch of approved biosimilars.

PhRMA: Federal Biosimilar Payment Policies Are Having a Positive Effect

Tony Hagen

March 4 2020

Katie Verb, director of policy and research for the biopharmaceutical industry group PhRMA, discusses recent policy changes that have increased biosimilar uptake and additional measures that could lead to greater use of biosimilars and savings for CMS and patients.

Amgen's Christl Says US Biosimilars Market Is on Solid Ground

Tony Hagen

March 3 2020

The US biosimilars market is showing healthy vital signs, said Leah Christl, Amgen’s executive director for global regulatory and research and development policy, in a talk kicking off the World Biosimilar Congress 2020 at the Festival of Biologics USA in San Diego, California, while also reassuring the audience that her former FDA colleagues are still champions of their work.